ADXS — Ayala Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.28m
- $4.21m
- $0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 98.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -278969.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.88 | 0.25 | 3.24 | 0.25 | 0.01 | n/a | n/a | -70.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.
Directors
- David Sidransky NEC (55)
- Kenneth Berlin PRE (56)
- James Patton NVC (63)
- Andres Gutierrez EVP (61)
- Igor Gitelman CAO (45)
- Roni Appel IND (54)
- Richard Berman IND (78)
- Samir Khleif IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 28th, 2002
- Public Since
- July 28th, 2005
- No. of Shareholders
- 117
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 42,633,400
- Address
- 9 DEER PARK DRIVE, SUITE K-1, MONMOUTH JUNCTION, 08852
- Web
- https://ayalapharma.com/
- Phone
- +1 6094529813
- Auditors
- Kost Forer & Gabbay
Upcoming Events for ADXS
Q3 2024 Ayala Pharmaceuticals Inc Earnings Release
Q4 2024 Ayala Pharmaceuticals Inc Earnings Release
Similar to ADXS
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Ayala Pharmaceuticals share price?
As of Today at 18:28 UTC, shares in Ayala Pharmaceuticals are trading at $0.03. This share price information is delayed by 15 minutes.
How has the Ayala Pharmaceuticals share price performed this year?
Shares in Ayala Pharmaceuticals last closed at $0.03 and the price had moved by -95.52% over the past 365 days. In terms of relative price strength the Ayala Pharmaceuticals share price has underperformed the S&P500 Index by -95.83% over the past year.
What are the analyst and broker recommendations for Ayala Pharmaceuticals?
The overall consensus recommendation for Ayala Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ayala Pharmaceuticals dividend yield?
Ayala Pharmaceuticals does not currently pay a dividend.
Does Ayala Pharmaceuticals pay a dividend?
Ayala Pharmaceuticals does not currently pay a dividend.
When does Ayala Pharmaceuticals next pay dividends?
Ayala Pharmaceuticals does not currently pay a dividend.
How do I buy Ayala Pharmaceuticals shares?
To buy shares in Ayala Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ayala Pharmaceuticals?
As of the previous close price of $0.03, shares in Ayala Pharmaceuticals had a market capitalisation of $1.28m.
Where are Ayala Pharmaceuticals shares listed?
Here are the trading details for Ayala Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ADXS
What kind of share is Ayala Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Ayala Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ayala Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Ayala Pharmaceuticals is $4.00. That is 13233.33% above the last closing price of $0.03.
Analysts covering Ayala Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Ayala Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ayala Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +49.81%.
As of the last closing price of $0.03, shares in Ayala Pharmaceuticals were trading -87.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ayala Pharmaceuticals PE Ratio?
The Ayala Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ayala Pharmaceuticals?
Ayala Pharmaceuticals' management team is headed by:
- David Sidransky - NEC
- Kenneth Berlin - PRE
- James Patton - NVC
- Andres Gutierrez - EVP
- Igor Gitelman - CAO
- Roni Appel - IND
- Richard Berman - IND
- Samir Khleif - IND